Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis - Takeaways - MDSpire

Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis

  • By

  • Geert D’Haens

  • Silvio Danese

  • Remo Panaccione

  • David T Rubin

  • Laurent Peyrin-Biroulet

  • Katsuyoshi Matsuoka

  • Edward V Loftus

  • Taku Kobayashi

  • Walid Elsharkawi

  • Rosa Miceli

  • Samia Ahmed

  • Yi Luo

  • Andrew Napoli

  • John Vaile

  • Quentin Dornic

  • Aditya Patel

  • Stefan Schreiber

  • May 13, 2025

  • 0 min

Share

  • 1

    Deucravacitinib is a selective TYK2 inhibitor investigated for efficacy and safety in Crohn's disease and ulcerative colitis.

  • 2

    Three phase 2 trials showed that deucravacitinib did not meet primary endpoints for clinical remission or response in IBD.

  • 3

    The studies included 239 patients with Crohn's disease and 169 with ulcerative colitis, with early termination for two trials.

  • 4

    Placebo groups exhibited high efficacy rates, indicating a lack of significant clinical benefit from deucravacitinib.

  • 5

    Deucravacitinib was found to be safe and well tolerated, with a safety profile consistent with its use in psoriasis.

Original Source(s)

Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis

  • by Geert D’Haens, Silvio Danese, Remo Panaccione, David T Rubin, Laurent Peyrin-Biroulet, Katsuyoshi Matsuoka, Edward V Loftus, Taku Kobayashi, Walid Elsharkawi, Rosa Miceli, Samia Ahmed, Yi Luo, Andrew Napoli, John Vaile, Quentin Dornic, Aditya Patel, Stefan Schreiber

  • May 13, 2025

Related Content

Progression of Coronary Calcium Detected on Routine Chest CT Enhances Cardiovascular Risk Assessment in Individuals with Inflammatory Bowel Disease: Findings from a Multicenter Study

REACHing forward—a strategic vision for ECCO and the future of IBD care

The role of lipid metabolism and creeping fat in disease assessment and prediction for Crohn’s disease